OpenFilings

REGENERON PHARMACEUTICALS, INC.

Form10-Q

Report Period2024-09-30

Date Filed2024-10-31

Time Filed07:16:48

Document Analysis

Natural Language Processing

Recognized Type Unidentified

Defined Term Format

Exhibits

10-Q
AMENDMENT NO. 3 TO MASTER AGREEMENT BETWEEN REGN AND ALNYLAM
CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)
CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)
CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C SECTION 1350
Filing on SEC Edgar